Drug-releasing cataract lens offers new approach to glaucoma

An experimental artificial lens implanted during cataract surgery could also provide long-term treatment for glaucoma, potentially eliminating the need for daily medication. Results from an early-stage clinical trial show that a lens releasing the glaucoma drug bimatoprost maintained eye pressure at levels comparable to conventional treatment with eye drops. After twelve months, more than 95 percent of patients receiving the experimental lens required no additional glaucoma medication.

The findings were presented at the annual meeting of the American Academy of Ophthalmology (AAO) in October 2026. The technology could offer a new treatment option for patients with both cataracts and glaucoma, two common eye conditions that frequently affect older adults. Although the initial results are promising, larger clinical trials and longer follow-up are needed to establish the treatment's long-term effectiveness and safety.

Combining two treatments

Cataracts develop when the eye's natural lens becomes cloudy, gradually reducing vision. Surgery involves removing the affected lens and replacing it with an artificial intraocular lens. Glaucoma, meanwhile, damages the optic nerve and can lead to irreversible vision loss. Elevated intraocular pressure is an important risk factor, and lowering this pressure remains the principal proven strategy for slowing disease progression. Many patients rely on daily eye drops to control their condition. However, maintaining consistent treatment can be difficult, particularly for older patients who may have problems administering medication or managing complex treatment schedules.

Researchers have therefore developed an intraocular lens that combines vision correction with sustained drug delivery. The experimental lens incorporates two small drug-containing pads that gradually release bimatoprost directly into the eye. Bimatoprost is already widely used to lower intraocular pressure, but the new approach eliminates the need for patients to administer the medication themselves. Jeffrey Kammer, an ophthalmologist at Vanderbilt University Medical Center and an investigator in the study, believes the technology could simplify treatment for patients who already require cataract surgery. Rather than introducing an additional procedure, the drug-delivery system becomes part of the artificial lens implanted during standard cataract surgery.

Eye pressure stable after twelve months

The phase 1/2 clinical trial involved 106 adults with mild-to-moderate open-angle glaucoma or ocular hypertension who were scheduled for cataract surgery. Participants were randomly assigned to receive either an experimental lens containing a lower or higher dose of bimatoprost or a conventional artificial lens combined with twice-daily timolol eye drops. After twelve months, average intraocular pressure had fallen to 15.9 mmHg in the higher-dose group and 14.8 mmHg in the lower-dose group. Patients receiving standard lenses and timolol drops recorded an average pressure of 15.7 mmHg.

These findings suggest that the drug-releasing lenses can achieve pressure reductions comparable to conventional medication during the first year after surgery. Importantly, more than 95 percent of patients receiving the experimental lenses did not require additional glaucoma medication at the twelve-month assessment. For patients, this could reduce the burden of daily treatment and eliminate difficulties associated with administering eye drops consistently.

However, the results do not establish that the experimental lens prevents long-term vision loss or offers superior protection against glaucoma progression. The study participants will be monitored for three years to assess the durability of pressure control and potential complications. Two larger clinical trials are also underway. The findings should currently be regarded as preliminary because they were presented at a scientific conference rather than published as a complete peer-reviewed clinical trial report.

Innovation extends beyond artificial lenses

The experimental implant illustrates how cataract surgery is evolving through new medical technologies. Innovation increasingly focuses not only on restoring vision but also on improving surgical procedures, clinical outcomes and the organisation of ophthalmic care. Earlier, we reported on research into AI for analysing cataract surgery videos. An international research team involving the University of Bonn developed an AI model capable of recognising different stages of small-incision cataract surgery.

Using the publicly available SICS-105 dataset, containing recordings of 105 operations performed at Sankara Eye Hospitals in India, researchers trained a deep-learning model that identified surgical phases with more than 85 percent precision. The technology could eventually support surgical training, quality assessment and the identification of deviations from standard procedures. Further development also focuses on recognising surgical instruments and potential complications.